We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Rapid, High Throughput Preformulation with Avacta’s Optim® 1000

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Avacta Analytical’s Optim® 1000 - a unique high throughput, micro-volume protein analysis and characterization system - is proving a valuable asset to scientists at the Macromolecule and Vaccine Stabilization Center (MVSC), University of Kansas, USA.

Professor C. Russell Middaugh explained: “Conventional analytical techniques used in preformulation, stability and formulation studies rely on methods that extrapolate partial data on slow and labour intensive instrumentation, making them incompatible with high throughput measurements and tight development timelines. We have developed a faster and more comprehensive approach, which depends on the measurement of all potential variables. The results are then processed mathematically using specially developed software, and are represented visually using empirical phase diagrams.”

“Ideally, a replicate series of results is acquired for each parameter and, although a variety of instruments can be used for individual measurements, this type of equipment tends to rely on relatively time-consuming processes and can generally handle only low throughputs. Sample volume is also an issue, since many conventional techniques require large amounts of the target molecule. The Optim 1000 provides rapid, multi-modal analysis of ultra-low sample volumes at high throughputs, precisely the kind of replicate measurements we need to generate data in a timely manner. Combining multiple technologies in a single instrument is already making in-roads into preformulation and formulation studies, and this approach is proving a real asset to researchers involved in the drug development process.”